跳至主要内容
临床试验/NCT02582502
NCT02582502Unknown不适用

Hyperbaric Oxygen Post Established Stroke - HOPES - Study

University of British Columbia1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2015年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
140
试验地点
1
主要终点
Change in the Stroke Impact Scale (SIS-16) from baseline over the duration of the study

研究概览

简要总结

The purpose of this study is to examine the role of Hyperbaric Oxygen Therapy (HBOT) in improving neurological function in patients who are 6 to 36 months post ischemic stroke.

详细描述

The purpose of this study is to examine the role of Hyperbaric Oxygen Therapy (HBOT) in improving neurological function in patients who are 6 to 36 months post ischemic stroke.

Hyperbaric oxygen therapy (HBOT) involves the administration of inhaled 100% oxygen at increased ambient pressure inside a closed vessel. HBOT produces greatly elevated arterial and tissue oxygen tensions, producing a wide variety of physiological effects at the cellular and sub cellular level. Some of these effects have been postulated to be beneficial in the context of ischemic stroke.

Most of the recovery after stroke occurs in the first 30 to 90 days after the acute event. Recovery is largely based on recovery of brain that is injured, but viable. Physiological imaging studies (PET, EEG) have demonstrated that brain tissue may remain alive but not functional for months or years after ischemic insult.

Subjects will be selected from the stroke population based on an expectation that they would experience a clinically significant improvement. Eligible subjects will have suffered an ischemic stroke involving the cerebral cortex within the last 6 to 36 months. The study will be enrolling 140 subjects and will be randomized to two different treatment arms: experimental group and a waitlist group.

Each subject will receive a series of forty 2 hour treatments, delivered once a day, 5 days a week, within the hyperbaric oxygen chamber.There will be assessments completed before treatment series begins, 3 weeks and 6 weeks into treatment and then again at the end of treatment. After treatment ends, the investigators will conduct these assessments again at 3 months, 6 months, 9 months and 1 year from the date of the participants last treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age between 19 and
  • •Able to speak English and give informed consent or have a substitute decision maker and able to assent.
  • •One or more ischemic stroke(s) involving the cerebral cortex or cerebellum within the last 6 to 36 months
  • •Able to sit in the chamber with the assistance of a waist and chest strap for 120 minutes.

排除标准

  • •Contraindication to HBOT (Appendix C) including:
  • •Untreated collapsed lung (pneumothorax)
  • •Have taken the chemotherapy drug Doxorubicin within 72 hours
  • •Have taken the chemotherapy drug Bleomycin within 4 months
  • •Bowel obstruction
  • •Heart pacemaker of unknown make and model
  • •Cigarette Smoking
  • •Chronic Obstructive Pulmonary Disease (COPD)
  • •Participation in other stroke related studies.
  • •Previous history stroke > 36 months prior to study baseline

研究组 & 干预措施

Treatment

Experimental

This arm will receive Hyperbaric Oxygen Therapy immediately after consent into study.

干预措施: Hyperbaric Oxygen (Other)

Wait list Treatment

Other

This arm will receive Hyperbaric Oxygen Therapy two months after consenting into study.

干预措施: Hyperbaric Oxygen (Other)

结局指标

主要结局

Change in the Stroke Impact Scale (SIS-16) from baseline over the duration of the study

时间窗: Pre treatment (Baseline and after waiting period is completed), During Treatment (3 weeks, 6 weeks) and Post Treatment (9 weeks post baseline, 8 months post and 14 months)

次要结局

  • 6 minutes walk test(Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post))
  • 6 metre walk test(Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post))
  • Digital Symbol Substitution Test(Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post))
  • Nine hole peg board(Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post))
  • Berg Balance Test(Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post))
  • Health Economics Questionnaire(Pre treatment (Baseline and after waiting period) and Post Treatment (5 months, 8 months, 11 months and 14 months))
  • Grip Strength(Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post))
  • National Institute of Health Stroke Scale (NIHSS)(Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post))
  • Trail Making Test(Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post))
  • Centre for Epidemiologic Studies Depression Scale (CESD)(Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post))
  • Medical Outcomes Study Short Form (SF-36)(Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post))
  • Montreal Cognitive Assessment (MoCA)(Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

David Harrison

Principal Investigator

University of British Columbia

研究点 (1)

Loading locations...

相似试验